The announcement came amid a slump in the company's share price and investor concerns about its experimental drug pipeline ...

New research has revealed that people taking weight loss drugs like Wegovy and Mounjaro are increasingly more likely to ...

Ozempic, which accounts for 41 percent of Novo Nordisk’s sales, is an injectable treatment for diabetes that became wildly popular on social networks for its slimming properties.

Weight loss therapeutics is a lucrative market and one that has now landed Novo Nordisk DKK65.1 billion, or more than US$10 billion, in profits – with nearly half of this from 2024 alone.

Ozempic pens being assembled at the Novo Nordisk factory in Hillerod, Denmark. (Charlotte de la Fuente for The Wall Street Journal) Shares of Europe's most valuable company rallied around 3.6% in ...